Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

NeuroVive Pharmaceutical: NeuroVive’s Chief Operating Officer Jan Nilsson Leaves the Company

Neurovive Pharmaceutical
Posted on: 24 Aug 16

Regulatory News:

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that its Chief Operating Officer, Jan Nilsson leaves the company.

The company is entering into a very important period and is expecting exciting developments during the fall. Over the past several months, the business strategy and organization have been re-oriented to optimize the way forward. As one consequence the position of COO is no longer required.

“I have been involved in NeuroVive in different roles since 2010 and it has been fantastic to be part of the development of the company to the position it holds today. The company has a very interesting project portfolio and a strong organization. The transition to our new CEO is now concluded which makes the timing right for me to seek new challenges. I will of course follow the company’s continued development with greatest interest”, says Jan Nilsson.

“Jan Nilsson has with great dedication, in combination with his vast knowledge and experience, played a key role in NeuroVive, not only as COO but also as a Director and for a period as interim CEO. Jan has been instrumental in managing the challenges faced by NeuroVive in recent years. On behalf of the entire company and its shareholders, I express our respect and appreciation for Jan and wish him all the best in his new endeavors”, says Greg Batcheller, Chairman of NeuroVive.

About NeuroVive

NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive's business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe.

NeuroVive's portfolio consists of two clinical projects, one in acute kidney injury (CicloMulsion®) and one in traumatic brain injury (NeuroSTAT®). The candidate drug NeuroSTAT has orphan drug designation in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in the CHIC study. CicloMulsion is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. Furthermore, the R&D portfolio consists of two late stage discovery programs and one compound in preclinical development.

NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market.

NeuroVive Pharmaceutical AB (publ) (STO:NVP) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48 www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on August 24, 2016.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160823006368/en/

Business Wire
www.businesswire.com

Last updated on: 24/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.